MedPath

a Study of EGFR & ALK Test in Lung cancer patients.

Not Applicable
Completed
Conditions
Health Condition 1: null- Lung Cancer Patients
Registration Number
CTRI/2017/10/010086
Lead Sponsor
Tata Memorial Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
500
Inclusion Criteria

Specimens with adequate tumor burden ( >50% of tumors cells) will taken for the FISH

analysis. The assessment will be done by a pathologist on the H&E.

Exclusion Criteria

No Exclusion criteria as the study is to be done only on the Tumor tissue blocks.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The Specific aims of the proposed study are to conduct a large-scale study among Lung Cancer patients in <br/ ><br>India to <br/ ><br>a) Estimate the prevalence of EGFR and EML4-ALK fusion in Indian NSCLC (adenocarcinoma) patient population; <br/ ><br>b) Evaluate the association of EGFR and EML4-ALK fusion with clinical and pathologic parameters of <br/ ><br>NSCLC (adenocarcinoma) and patient characteristics; <br/ ><br>Timepoint: End of the study
Secondary Outcome Measures
NameTimeMethod
ot applicableTimepoint: Not Applicable
© Copyright 2025. All Rights Reserved by MedPath